About Us
The GI Company is a privately held, specialty biopharmaceutical company established to meet the clinical needs and commercial opportunities available in the field of gastrointestinal medicine.
The GI Company's strategy for success is to:
| Focus: |
|
Discover and develop products in key gastrointestinal indications with high medical need. |
|
|
|
| Deliver: |
|
Identify and exploit "development-ready" technologies for the near-term to reduce risks for shareholders. |
|
|
|
| Build: |
|
Build a novel pipeline of products based on cutting-edge science in the gastrointestinal field, through leveraging resources from academic institutions and corporate partners. |
Clinical and Commercial Opportunity in the GI Field
There are numerous therapeutic opportunities in the gastrointestinal field including disorders for which there is no current treatment available or for which the current treatment is less than effective or produces unpleasant and sometimes harmful side effects. In the U.S. alone, the number of patients who could benefit from enhanced therapeutics is enormous, considering the statistics on the numbers of individuals in the U.S. with the following gastrointestinal conditions:
• Mucositis (350,000–400,000)
• Motility Disorders (>15,000,000)
• Chronic Hepatitis and Cirrhosis (8,000,000)
• Inflammatory Bowel Diseases (1,000,000)
• Reflux Disease and Barrett's Esophagus (16,000,000)
• Gastric Damage, for example by NSAID Gastropathy (>1,000,000)
• Necrotizing Enterocolitis (50,000)
• Gastrointestinal Cancers (1,000,000)
The mission of The GI Company is to develop and produce novel and effective therapeutics for the treatment of patients suffering from these and other gastrointestinal diseases.
|
